TCRX
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- TScan Therapeutics announced a strategic reorganization focused on in vivo cell therapy for solid tumorsSep 7, 2026
- TScan Therapeutics reported positive initial Cohort C data from the Phase 1 ALLOHA study of TSC-101 in hematologic malignanciesJun 22, 2026
- TScan completed enrollment in Cohort C of the Phase 1 ALLOHA™ trial and received FDA clearance for INDs of TSC-102-A01 and TSC-102-A03Feb 26, 2026